Management reviews new data from the Company’s Phase 1 Clinical Trial of BTK Degrader NX-5948 on a conference call to be held on December 9 at 11 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics initiated with an Outperform at BMO Capital
- Nurix Therapeutics announces PRIME designation for NX-5948 from EMA
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
- Nurix Therapeutics initiated with a Buy at UBS
- Nurix Therapeutics price target raised to $30 from $26 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com